Drugs / vabicaserin
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00928551 | Jun → Sep 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00541996 | Aug → Oct 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00505973 | Jul → Oct 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00458107 | Apr → Sep 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00420706 | Dec 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00447941 | Jun → Aug 2006 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00768612 | Nov 2008 → Jul 2009 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00563706 | Dec 2007 → Jun 2008 | schizophrenia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00265551 | Jan 2006 → Jan 2007 | schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vabicaserin | “A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia” NCT00768612 ↗ |
| Known as | SCA-136 | “A Randomized, Open-Label, Single-Dose, 4-Period Crossover, Comparative Bioavailability Study of 3 Sustained- Release Formulations and an Immediate- Release Formulation of...” NCT00541996 ↗7“The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute...” NCT00563706 ↗ “A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia” NCT00768612 ↗ |
| Known as | VABICASERIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110670 ↗ |
| Known as | Vabicaserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110670 ↗ |
| Known as | Vabicaserine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110670 ↗ |
| Action | Activate | “Serotonin 2c (5-HT2c) receptor agonist” CHEMBL2110670 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL2110670 ↗1“Serotonin 2b (5-HT2b) receptor antagonist” CHEMBL2110670 ↗ |
| Modality | Small molecule | — CHEMBL2110670 ↗ |
| Route | Oral | “Administered Orally” NCT00447941 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL2110670 ↗ |
| Target | HTR2B | “Serotonin 2b (5-HT2b) receptor antagonist” CHEMBL2110670 ↗ |
| Target | HTR2C | “Serotonin 2c (5-HT2c) receptor agonist” CHEMBL2110670 ↗ |